The anti-CCR4 antibody mogamulizumab has been shown to reduce peripheral Treg counts in patients, leading to regulatory approval for the treatment of peripheral T cell lymphomas in Japan [23]. Here, CCR4 is linked to peripheral T-cell lymphoma, not otherwise specified.